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Abstract
Background: Most inoperable patients with esophageal-advanced cancer (EGC) have a poor prognosis. Esophageal stenting,
as part of a palliative therapy management has dramatically improved the quality of live of EGC patients. Airway stenting is
generally proposed in case of esophageal stent complication, with a high failure rate. The study was conducted to assess the
efficacy and safety of scheduled and non-scheduled airway stenting in case of indicated esophageal stenting for EGC.
Methods and Findings: The study is an observational study conducted in pulmonary and gastroenterology endoscopy
units. Consecutive patients with EGC were referred to endoscopy units. We analyzed the outcome of airway stenting in
patients with esophageal stent indication admitted in emergency or with a scheduled intervention. Forty-four patients
(586\28 years of age) with esophageal stenting indication were investigated. Seven patients (group 1) were admitted in
emergency due to esophageal stent complication in the airway (4 fistulas, 3 cases with malignant infiltration and
compression). Airway stenting failed for 5 patients. Thirty-seven remaining patients had a scheduled stenting procedure
(group 2): stent was inserted for 13 patients with tracheal or bronchial malignant infiltration, 12 patients with fistulas, and 12
patients with airway extrinsic compression (preventive indication). Stenting the airway was well tolerated. Life-threatening
complications were related to group 1. Overall mean survival was 26+/210 weeks and was significantly shorter in group 1
(6+/27.6 weeks) than in group 2 (28+/211 weeks), p,0.001). Scheduled double stenting significantly improved symptoms
(95% at day 7) with a low complication rate (13%), and achieved a specific cancer treatment (84%) in most cases.
Conclusion: Stenting the airway should always be considered in case of esophageal stent indication. A multidisciplinary
approach with initial airway evaluation improved prognosis and decreased airways complications related to esophageal
stent. Emergency procedures were rarely efficient in our experience.
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Introduction
Management of advanced esophageal cancer (EGC) is still a
medical and technical challenge [1]. Most of the inoperable
patients are unable to swallow food, and therefore undergo
intravenous alimentation with related nosocomial complications.
In case of esophagotracheal or bronchial fistulas, the immediate
prognosis is poor resulting in continuous aspiration, mediastinis
and pneumonia [2].
Esophageal stenting dramatically improved patients quality of
live with a restoration of natural alimentation [3–6]. However, in
many cases, patients secondarily experienced cough and difficul-
ties in breathing. Acute airway obstruction with asphyxia was
described after esophageal stent insertion (figure 1, 2). This
complication was related to the esophageal stent protrusion in the
airway (figure 1) [7–9]. Double stenting has been proposed for the
management of esophago-tracheal fistulas [10–15].
The aims of this study were to assess the outcome of scheduled
and non-scheduled airway stenting, as well as the impact of
adequate bronchoscopic evaluation on quality of life and survival




44 consecutive patients (37 males and 7 females, mean age
586\28) were analyzed between 2001 and 2007. All patients had
a diagnosis of esophageal carcinoma (squamous cells or adeno-
carcinoma) and were not considered candidates for surgery due to
advanced staging. All these 44 patients were indicated for
esophageal stenting. All patients were referred to our bronchos-
copy department by patient’s gastroenterologist. CT scan was
initially performed and analyzed. Flexible bronchial fibroscopy
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procedure in order to describe airway abnormalities and confirm
the indication for an interventional procedure. The latter was the
result of a multidisciplinary staff including thoracic surgeon, ENT,
digestive endoscopist and an experienced interventional bronchos-
copist. Airway findings were classified as follow: 1- esophageal
fistulas with trachea and/or main bronchi 2- malignant infiltration
of the airway (requiring debulking or not) 3- extrinsic compression
of parts of the airway with no malignant infiltration. In general,
airways stenting was only proposed if esophageal stent insertion
was indicated. In case of fistula and/or malignant infiltration of
the airways, a double stenting was systematically proposed. In case
of extrinsic compression, an airway stent was proposed in patients
with lumen patency lower than 40% or or with bronchial secretion
retention below compression. For less severe extrinsic compres-
sion, an airway stenting was proposed as a preventive indication to
avoid complications induced by the esophageal stent.
Stent placement
Esophageal stent placement. All procedures were
performed under general anesthesia. A guide wire was inserted
through the fibroscope (Olympus, Tokyo, Japan), across the tumor,
and into the distal portion of the esophagus or stomach with
fluoroscopic guidance. In severe stricture, a deflated balloon
catheter with a 10–12-mm-diameter balloon was then passed over
the guide wire to a position across the stricture. The balloon was
slowly inflated until the hourglass deformity created by the stricture
disappeared from the balloon contour. A metallic covered stent
(Ultraflex, Boston scientific, USA) at least 4 cm longer than the
stricture was then placed so that its proximal and distal parts rested
on the upper and lower margins of the stricture. In case of fistula the
covered part of the stent was placed to close the opening. A visual
control was performed at the end of the procedure to check the re-
opening of the esophagus and/or the fistula closure.
Tracheal and/or bronchial stent placement
technique. All procedures were performed under general
anesthesia with a rigid bronchoscope (EFER, La Ciotat, France).
In case of intraluminal malignant proliferation, YAG-laser
(Kontron, Eching, Germany) photoablation, or electrocautery
(ERBE, Tu ¨bingen, Germany) was performed in order to restore
airway caliber before airway stenting (Ultraflex, Boston scientific,
USA; Dumontstent, Novatech,LaCiotat, France). When needed,a
dilation balloon was used to restore airway diameter. The balloon
technique was identical as for esophageal stent placement.
Prosthetic material was inserted as needed and immediately
repositioned under visual control when required as
recommended. In case of fistula, the covered part of the stent was
placed to cover the opening, and the total length was calculated so
that the non-covered bottoms of the stents were in a non-pathologic
area of the airway.
Timing of both procedures. We tried to insert the airway
stent first, to avoid compression of the airway by the esophageal
stent. In 13 cases both stents placement were performed during the
same procedure, the airway stent first.
Evaluation and follow-up
All the data were prospectively recorded. Evaluation of airway
stenting was performed immediately and within the 1
st week after
insertion. Follow-up data was collected in 38 patients.
All patients gave a signed inform consent describing the
interventional procedure. The study was submitted to and
Figure 1. Perforation of the trachea by an esophageal stent.
The carina and the main left bronchus were severely injured. The initial
fibroscopy performed before esophageal stenting, showed a slight
intrinsic compression of the lower part of the trachea and main left
bronchus.
doi:10.1371/journal.pone.0003101.g001
Figure 2. Severe compression of the left main bronchus
induced by an esophageal stent. The patient experienced
aspiration pneumonia.
doi:10.1371/journal.pone.0003101.g002
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la Recherche Clinique du CHR/GHSR). According to French
regulations, no ethic approval was mandatory as patients
underwent only standard diagnosis and treatment.
Statistical analysis
Data are reported in mean+/2standard deviation or percent-
age. The Mann-Withney U-test was used to assess differences in
continuous variable. Clinical factors, therapeutic issues in patient
in group 1 vs group 2 were analyzed using the x2 or Fisher’s exact
test. Survival difference between sub-group was assessed by
Kruskall Wallis test. Variables with a p-value less than 5% were
considered as statistically significant. Analyses were performed
with StatView 2 software, abacus concept, inc, USA.
Results
Patient’s characteristics, general conditions and outcome are
listed in table 1 and in table 2. Among the 44 patients, 7 were
referred in emergency due to esophageal stent-related airway
complications (group 1). Among these 7 patients, 3 of them
received a bronchial fiberoptic evaluation prior to esophageal
stenting that revealed a fistula (one patient), a slight extrinsic
bronchial compression (one patients), and a complex infiltration
and stenosis of the carena and the left bronchus (one patient).
Time between esophageal stenting and emergency admission for
respiratory complications was 8.5+/29 days (range 2–29). The 37
remaining patients were referred by a multidisciplinary staff for a
scheduled stent intervention (group 2). Among the 44 patients, 17
(38.5%) had a fistula, 14 (32%) a malignant infiltration, and 13
(32.5%) an extrinsic compression of the airway. The percentage of
lumen obstruction induced by extrinsic compression was assessed
by visual evaluation during bronchoscopy, and ranged from 5 to
60% (mean 29+/212). Fifteen (34%) patients had a tracheal
involvement, 17 (38.6%) had a left bronchial involvement. We
diagnosed a tracheal, carina, and both main bronchi malignant
proliferation in 9 (16%) patients. Three (5%) patients had a
tracheal and main left bronchus involvement. A deobstruction
procedure was necessary for 16 patients. A single left bronchial
metallic stent (16 mm in diameter, 40 mm in length) was inserted
in 19 cases, a Y Dumont stent in 4 cases (various adapted size), and
a tracheal metallic stent (18 to 20 mm in diameter, 60 to 80 mm in
length) in 17 cases. Two patients had a double bronchial stent
(Dumont stent for the right bronchus, metallic stent for the left
bronchus), and 2 patients a tracheal and left bronchial metallic
stent. Airway stenting was impossible for 5 patients.
Complications of the procedure are presented in table 3.
1- Esophageal stent complications
1a- in the esophagus. partial opening in 4 patients, non-
malignant granuloma at the upper part of the stent in 6 patients
(requiring LASER photoablation in 2 cases and, an additional
stent within the original esophageal in 4 cases), major throat pain
due to a stent inserted for a fistula of the upper part of the
esophagus for 1 patient (stent was removed at day 2, and the
tracheal stent was efficient alone to close the opening), tumor
overgrowth in 2 patients (related to a rapid progression of the
disease). Food bolus impaction was easily managed for 2 patients.
Stent migration was low and observed in only 2 patients (5.5%).
1b- in the airway. one patient with a left bronchial stent had
a non-symptomatic compression due to the esophageal stent.
Major complications occurred in the 7 patients admitted in
emergency. Five had a protrusion of the esophageal stent in the
airway (4 involving the carina) resulting in a major fistula and
airway obstruction. One patient had extrinsic compression of the
trachea with malignant proliferation requiring urgent LASER
deobstruction. One patient had a major compression of the main
left bronchus. It was impossible to insert an airway stent for 5 of
these patients, who unfortunately rapidly died (table 2).
2- Airway stent complications
Airway stents were well tolerated. All patients were asked to
perform nebulisation with saline twice a day to avoid airway stent
obstruction. Transient pain was observed for 22 (50%) patients.
One patient had uncomfortable bad breath. We did not observe
any migration for the 26 patients with fistula and esophagotracheal
or bronchial malignant proliferation. One preventive bronchial
stent migrated after chemotherapy application due to a significant
reduction in tumor volume, and was easily removed. Partial
bronchial stent obstruction with secretions was observed in 2 cases
(easily controlled). A secondary fistula of the carina occurred in 2
patients with double bronchial stents (a Y Dumont stent was
inserted after difficult extraction of the metallic stent for 1 patient.
No further complication was related for the other one). We
observed 4 granulomas at the upper part of the airway stent (1
only required laser therapy, with no relapse).
The impact of stenting is presented in table 4. Respiratory
symptoms were improved on day1 and 7 (p=0.004; RR 3.5: 2–7
Table 1. Patient’s characteristics.
Number of patients (%) N=44














Aspiration pneumonia 15 (34%)
Miscellaneous{ 7 (16%)
Emergency admission 7 (16%)




Time of bronchial stenting*
Previous 23 (52%)
During same procedure 13 (29.5%)
After 8 (18%)
{Miscellaneous symptoms (fatigue, fever, chest pain).
*Referral time was esophageal stent insertion.
FOB: Fiberoptic bronchoscopy.
doi:10.1371/journal.pone.0003101.t001
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radiotherapy was administered in 26 patients, the over 18 patients
had best supportive care. Planned EGC therapy was administrated
in 1/5 patient in group 1 and in 25/26 patients in group 2
(p,0.001; RR 20.8: 3–150). Mean survival was 26+/210 weeks
(range: 1–54). Survival was significantly shorter in group 1 patients
(6+/27.6 weeks; range1–22) than in group 2 patients (28+/211
weeks; range 2–54)) (p,0.001). In group 2, we did not observe
survival differences between the 3 sub-groups (fistula, malignant
proliferation and, compression). To date, 6 patients are still alive.
Discussion
We report here 44 attempts of double stenting involving both the
airway and the esophagus in patients with advanced esophageal
cancer (EGC). Double stenting was successfully performed in 39
Table 2. Comparison of demographic data general conditions and cause of death in patients in group 1 and group 2.
Group 1 Group 2 P value
N=7 N=37
EGC staging (M0/M1) 3/4 27/10 0.18
Initial performans status
O–1 4 24 0.69
2–4 3 13
Respiratory symptoms before esophageal stenting 5/6 (83%) 36/37 (97%) 1
Acute severe symptoms after esophageal stenting 7/7 (100%) 7/37 (19%)* P,0.0001
Time between stenting and death (weeks) 6+/27.6 28+/211 P,0.001
Cause of death
Immediate airway complications 6/7 (86%) 0 P,0.0001
Late airways complications 0 3/31 (9.5%)
Pleural effusion 0 4/31 (13%)
Evolution of EGC 0 20/31 (65%)
Unknown 0 4/31 (13%)
MO/M1: presence or absence of EGC metastasis.
*Acute severe symptoms in group 2 are chest pain for 6 patients and a transient shortening of breath for 1 patient.
doi:10.1371/journal.pone.0003101.t002





Stent1 Severe complication Non severe complication Survival (For 38 patients)
Group 1 7
Fistula 4 1 T. Metallic: 1 AP: 3 Transient pain: 1 Died 18 w.
1 Impossible: 3 SS: 1 3 patients died within 1–3 w
Malignant proliferation 1* 1 Impossible ARF Died 2 w.
Compression 1 B Metallic: 1 None Alive (20 w.)
Other/Complex 1{ 1 Impossible AP+ARF+hemoptysis Died during intervention
Group 2 37
Fistula 13 1 T Metallic: 5 Stent obstruction: 2 Transient pain: 7 22+/211 w
B Metallic: 6, YDS: 2 Granuloma: 2 2 alive (30 w.)
Malignant proliferation 12 11 T Metallic: 4, B
Metallic: 8
Fistula after RT: 1 Transient pain: 8 24+/29w .
DS: 2, YDS: 1 Granuloma: 1 all deceased
Compression 12 0 T Metallic: 7 Migration: 1 Fistula after Bad breath: 1 Transient pain: 6 27+/212 w.
B Metallic: 4, YDS: 1 RT: 1 Granuloma: 1 4 alive (33 w.)
EC: electrocautery. AP: Aspiration pneumonia. SS: septic shock. T: Tracheal. B: Bronchial. DS: Dumont stent. YDS: Y Dumont stent. W.: weeks. RT: Radiotherapy.
1The number of stents exceeded the number of cases as some patients had multiple stents insertion.
*With ARF (acute respiratory failure) at admission.
{Double fistula of the middle trachea (not related to esophageal stent) and carina. The carina and the 2 main bronchi were destroyed by the esophageal stent.
Malignant infiltration was observed. Left bronchus was totally obstructed.
doi:10.1371/journal.pone.0003101.t003
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emergency. Emergency procedures led to poor outcome while
scheduled procedures were associated with a better prognosis. We
emphasized the potential value of a preventive airway stenting
before esophageal procedures in cases of extrinsic compression.
Stenting the esophagus has dramatically improved the quality of
life of patients with end-stage esophageal cancer. While esophageal
stent usefulness has been published a decade ago [7–16], advanced
EGC with airway involvement is still a challenging condition for
physicians. There are no current guidelines for esophageal stent
procedures advising for bronchoscopy prior to stent insertion.
Stridor or wheezing may be induced during esophageal dilation
with a bougie or a balloon, therefore suggesting major compres-
sion of the airways. However, we think that routine evaluation of
the airways by fiberoptic bronchoscopy should be mandatory for
the evaluation of EGC.
We observed that emergency procedures were associated with a
poor prognosis when compared to scheduled procedures. The 7
patients admitted in emergency were referred to the bronchoscopy
suite because of respiratory symptoms occurring immediately or
shortly after esophageal stent procedure due to wall injury,
protrusion in the airway, or dramatically increased preexisting
extrinsic compression. In these cases, the pulmonary interventional
procedure was found extremely difficult, resulting in failure of
airway stenting in 5 cases. One patient died during intervention
and, the 4 others deceased within 3 weeks. There are no possibilities
to conduct any trial, neither blinded nor controlled, in these
emergency palliative situations. Therefore, airway fibroscopy
should be discussed as soon as possible for all EGC patients at the
time of CT scan examination or esophageal management.
Fortunately, in most patients, a multidisciplinary approach
allowed to schedule bronchial stenting before esophageal stenting.
Three main indications were considered: fistula, malignant
invasion and extrinsic compression. The latter can be considered
as a preventive procedure not reported yet.
In case of confirmed esophagotracheal fistula, an airway
placement stent to counteract the compression induced by the
esophageal device has already been proposed by several groups
[10–12,17,18]. In these cases we systematically inserted tracheal,
bronchial or Y Dumont stents. To our opinion, double stenting
present the following advantages in patients with oesphageal
fistula: i) prevent the protrusion of the esophageal stent in the
airway ii) increase the fistula closure by the airway stent iii)
decrease stent migrations as both stents interact with each other.
Malignant invasion of the airway was the second indication
considered for double stenting. Initial LASER or electrocautery
desobstruction+/2additional mechanical debulking was often
needed to restore a satisfactory opening of the airway lumen. In
these situations, the mechanical properties of the airway wall were
severely compromised. Once again, the insertion of the esophageal
stent might increase the airway obstruction. The airway stent was
then used to restore a tracheal or bronchial framework. In these
cases, double stenting can be considered useful to maintain an
acceptable airway and avoid a major risk of fistulisation in cases
where chemotherapy or radiotherapy is planned.
Preventive stent insertion was the third situation. To our
knowledge, this is the first report describing this indication.
Extrinsic compressions of the airway were the only findings in 12
patients. Due to the asymptomatic nature of these airway
compressions we proposed a preventive airway stenting in the
narrowed area of the airway before esophageal stenting. It is
difficult to predict outcome of an esophageal stent insertion alone.
Esophageal stent complications were extensively described in the
literature [19–28] and, depend on the type of stent used. Older
stents (Z stents, wallstents) are more related with complications
than modern stents (Ultraflex, polyflex) [27,28]. Early complica-
tions as perforation are variable and ranges from 2 to 20% [22].
Later complications as fistula are also variable (0–10%). Wang et
al reported major complications (perforation fistula) in 16% of
patients [27] and a review reported up to 30% of these
Table 4. Impact of airway stenting on respiratory symptoms and, EGC therapy.
Group 1 Group 2 P value RR (95% CI)
N=7 N=37
Day 1 1 (14%) 28 (76%) p=0.004 RR 3.5 (2–7)
Improvement of respiratory symptoms
Day 7 2 (28%) 35 (95%) p,0.001 RR 13 (3–55)
Candidate for EGC therapy 5 (71%) 26 (70%) p,0.001
Achieved to receive therapy 1 (14%) 25 (96%) RR 20.8 (3–150)
Evolution (weeks) 6+/27.6 28+/211 P,0.001
Candidate for EGC therapy: (RT+/2CT)
Fistula 3 (43%) 9 (24%)
Malignant proliferation 0 7 (19%)
Compression 1 (14%) 10 (27%)
Complex 1 (14%) -
Achieved to receive EGC Therapy*
Fistula 0 9 (100%)
Malignant proliferation 0 6 (86%)
Compression 1 (100%) 10 (100%)
Complex 0 -
*% based on patients who were candidate for therapy. 95% CI: 95% confidence interval.
RR: relative risk. EGC: esophageal cancer. RT: Radiotherapy. CT: chemotherapy.
doi:10.1371/journal.pone.0003101.t004
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the risk of esophageal stent complications [28–30]. To our
opinion, these complication rates may be underestimated, as
airway examination was not reported. In recent reviews, some
authors drew attention to the risk of airway compromise when the
neoplasic mass narrows the trachea (figure 3) [30,31]. They
advised to consider airway evaluation and tracheo-bronchial
stenting in these high risk situations (malignant infiltration in the
proximal third part of the esophagus) [22,30,31]. Perforation and
fistula are major and life-threatening complications, and should be
avoided in these palliative situations where quality of life is the
major end point. We think that preventive double stenting may be
considered. Global improvement of respiratory symptoms and,
good tolerance of airway stents were major points to promote this
procedure. Moreover, scheduled stenting procedure allowed to
administer planned EGC therapy for 96% patients, compared to
the 14% in the emergency group. This approach may be beneficial
to EGC patients. By closing fistulas and decreasing airway
complications related to esophageal stenting, chronic aspiration,
chronic sepsis, and recurrent atelectasis were uncommon in
patients with scheduled airway stenting. Chemotherapy and/or
radiotherapy were administered with no delay. Covered metallic
stents (ultraflexH) were mostly used because of their high expansion
properties to counteract the larger and wider esophageal metallic
stent. In case of carina involvement, only Y silicone stents
(novatechH) were used. However, all recent marketed stents can
probably be considered for this indication depending on
physician’s experience [32].
The timing of double stenting is the last issue [31]. We tried to
insert the airway stent first. As the esophageal stent was always
longer and wider, the expansion strength was therefore greater. To
stent the trachea several days after the esophageal stenting may be
hazardous, and (may) require balloon dilation with a risk of
tracheal rupture [33]. In our experience, first stenting of the
airway was easy and safe. This should be assessed more
systematically.
Our study has several limitations. First, we didn’t conduct a
controlled study for preventive stents. However, we did not
observe any clear difference for prognosis suggesting that
preventive airway stenting did not interfere with the general
outcome. Blinded, randomised and controlled studies are difficult
to conduct in this patient population due to ethical and practical
considerations. Second, patient quality of life (QOL) was not
assessed by a validated scoring system. However, improvement of
respiratory symptoms was a major result of the procedure. As these
patients are considered incurable patients on palliative therapy,
survival was not considered an appropriate and relevant endpoint.
Time between stent insertion and recurrence of symptoms is a
better key point. However, end-stage EGC patients have multiple
entangled symptoms which makes it difficult to precisely assess
symptom recurrence. Moreover, specific GI signs often overshad-
ow respiratory symptoms. Last, we did not clearly evaluate the
impact of the esophageal stent on improvement of dysphagia and
general conditions (weight gain, recovery of oral intake). However,
our results should not be different as indicated in the literature.
In conclusion, our opinion is to consider double stenting in three
situations. 1- As a curative approach in case of a fistula and/or
malignant airway wall involvement. 2- As a preventive approach
in case of an extrinsic tracheal or bronchial compression, even
before any symptomatology 3- As a preventive approach in case of
a large proximal esophageal tumor when radiotherapy is
scheduled. Airway stents must be inserted before or during the
esophageal stenting to avoid secondary technical difficulties.
Due to the poor prognosis of EGC, esophageal stenting as a
palliative procedure may increase the general QOL. However
double stenting (airway and esophageus) may prevent secondary
emergency situations with life-threatening complications and
recurrent high hospitalization costs.
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